PROTEOMICS INTERNATIONAL LABORATORIES LIMITED Financials Proteomics International Laboratories Limited
Equities
PIQ
AU000000PIQ0
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 AUD | +3.81% |
|
-0.46% | +21.79% |
| Mar. 25 | Proteomics International Signs Agreement with University of Oxford for Endometriosis Study | MT |
| Mar. 19 | Proteomics Says PromarkerD's US Launch Delayed | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 98.31 | 104 | 142.7 | - | - |
| Enterprise Value (EV) 1 | 98.31 | 98.08 | 137 | 142.7 | 142.6 |
| P/E ratio | -18.6 x | -17.2 x | -18.8 x | -25.6 x | 105 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 31.3 x | 51 x | 24.2 x | 9.39 x |
| EV / Revenue | - | 29.5 x | 48.9 x | 24.2 x | 9.38 x |
| EV / EBITDA | - | -17.2 x | -20.4 x | -30.4 x | 71.3 x |
| EV / FCF | - | -14.2 x | -20.1 x | -25 x | 1,426 x |
| FCF Yield | - | -7.05% | -4.96% | -4% | 0.07% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 105,706 | 120,979 | 130,893 | - | - |
| Reference price 2 | 0.9300 | 0.8600 | 1.050 | 1.050 | 1.050 |
| Announcement Date | 8/30/22 | 8/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 3.321 | 2.8 | 5.9 | 15.2 |
| EBITDA 1 | - | -5.705 | -6.7 | -4.7 | 2 |
| EBIT 1 | - | -6.234 | -7.5 | -5.5 | 1.3 |
| Operating Margin | - | -187.73% | -267.86% | -93.22% | 8.55% |
| Earnings before Tax (EBT) 1 | - | -6.234 | -7.7 | -5.6 | 1.3 |
| Net income 1 | -4.973 | -6.234 | -7.7 | -5.6 | 1.3 |
| Net margin | - | -187.73% | -275% | -94.92% | 8.55% |
| EPS 2 | -0.0500 | -0.0500 | -0.0560 | -0.0410 | 0.0100 |
| Free Cash Flow 1 | - | -6.911 | -6.8 | -5.7 | 0.1 |
| FCF margin | - | -208.1% | -242.86% | -96.61% | 0.66% |
| FCF Conversion (EBITDA) | - | - | - | - | 5% |
| FCF Conversion (Net income) | - | - | - | - | 7.69% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/30/22 | 8/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 5.96 | 5.7 | - | 0.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -6.91 | -6.8 | -5.7 | 0.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -79.8% | - | - | - |
| Assets 1 | - | 7.808 | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 1.22 | 0.5 | 0.8 | 0.7 |
| Capex / Sales | - | 36.67% | 17.86% | 13.56% | 4.61% |
| Announcement Date | 8/30/22 | 8/21/23 | - | - | - |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.05
AUD
Average target price
1.38
AUD
Spread / Average Target
+31.43%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.79% | 90.89M | |
| +8.60% | 105B | |
| -1.06% | 104B | |
| +5.76% | 22.94B | |
| -12.76% | 22.34B | |
| -6.45% | 19.25B | |
| -39.98% | 17.08B | |
| -9.25% | 16.96B | |
| +7.74% | 14.16B | |
| +39.23% | 12.63B |
- Stock Market
- Equities
- PIQ Stock
- Financials Proteomics International Laboratories Limited